<DOC>
	<DOCNO>NCT00755196</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy AN2728 Ointment , 5 % , compare Ointment Vehicle , apply twice daily 12 week , treatment plaque type psoriasis</brief_summary>
	<brief_title>Safety Efficacy Study A Novel Ointment Treat Plaque Type Psoriasis</brief_title>
	<detailed_description>This single center , randomize , double-blind , vehicle-controlled , bilateral design . Patients apply test article , AN2728 Ointment , 5 % , Ointment Vehicle twice daily 12 week . The assigned study medication apply two comparable treatment target plaque identify baseline . One test article apply one plaque test article anatomically distinct plaque . All efficacy evaluation measure two plaque identify baseline visit .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Male female &gt; 18 year age time enrollment 2 . The clinical diagnosis stable plaque psoriasis 3 . Two target plaque similar severity ≥ 5 cm2 ≤ 100 cm2 compute multiply great diameter plaque diameter plaque perpendicular great diameter Bilaterally locate ( right/left ) plaques arm distinct plaque locate trunk . Plaques locate trunk must separate least 10 cm designate Investigator either left/right front/back upper/lower Overall target plaque severity score ( OTPSS ) 24 ( mild moderate ) 1 point difference score individual plaque 4 . Normal clinically significant screen laboratory result 5 . Willing able apply study drug direct , comply study instruction commit followup visit 6 . Ability understand , agree sign study Informed Consent Form ( ICF ) prior initiation protocol relate procedure 1 . Any dermatological condition could interfere clinical evaluation disease state physical condition might expose patient unacceptable risk study participation 2 . Any underlying disease ( ) dermatological condition require use exclusionary topical systemic therapy ( see ) . 3 . Known sensitivity component study medication 4 . Spontaneously improve rapidly deteriorate psoriatic plaque pustular/exfoliative , guttate , erythrodermic nonplaque form psoriasis 5 . Concomitant use topical systemic therapy might alter course psoriasis 6 . Females child bear potential . Females must postmenopausal surgically sterile ( oophorectomy ) . 7 . Washout period : Topical drug might alter course psoriasis : 2 week Oral retinoids : 8 week Nonretinoid systemic drug might alter course psoriasis : 4 week PUVA : 4 week UVB therapy : 4 week Use emollients/moisturizers area ( ) treat : 2 day baseline visit 8 . AIDS AIDS relate illness 9 . Concurrent participation another drug research study within 30 day enrollment 10 . Use lithium hydroxychloroquine containing product ( i.e . Plaquenil ) 11 . Use betablocking medication ( i.e . propranolol ) dose stabilize least 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Plaque Type Psoriasis</keyword>
	<keyword>Topical</keyword>
</DOC>